Literature DB >> 15211086

Moxifloxacin and biofilm production by coagulase-negative staphylococci.

C Pérez-Giraldo1, C Gonzalez-Velasco, R M Sánchez-Silos, C Hurtado, M T Blanco, A C Gómez-García.   

Abstract

The in vitro activity of moxifloxacin against 41 strains of coagulase-negative staphylococci was determined. A relationship between the activity of moxifloxacin and biofilm formation was detected. Biofilm-producing strains were more resistant to moxifloxacin than biofilm-negative strains. Our global results obtained with six strains of Staphylococcus epidermidis showed that subinhibitory concentrations of moxifloxacin did not significantly modify biofilm formation. On the other hand, moxifloxacin concentrations of 2, 10, 50 and 100 x MIC produced a log decrease in viable count (included in a biofilm) of 0.20, 0.37, 1.10 and 1.69, respectively. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15211086     DOI: 10.1159/000077811

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  4 in total

1.  Safety and efficacy of moxifloxacin monotherapy for treatment of orthopedic implant-related staphylococcal infections.

Authors:  Rafael San Juan; Ana Garcia-Reyne; Pedro Caba; Fernando Chaves; Carlos Resines; Fernando Llanos; Francisco López-Medrano; Manuel Lizasoain; Jose Maria Aguado
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

2.  In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.

Authors:  Kristi L Frank; Emily J Reichert; Kerryl E Piper; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2006-12-11       Impact factor: 5.191

3.  Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.

Authors:  Jorge Parra-Ruiz; Celine Vidaillac; Warren E Rose; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2010-08-09       Impact factor: 5.191

4.  Moxifloxacin in the treatment of skin and skin structure infections.

Authors:  David Rp Guay
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.